Inquiry Basket
Polymer-Based Small-Molecule Delivery Services
Small-Molecule Drug Delivery Solutions
BOC Sciences provides polymer-based small-molecule drug delivery solutions for solubility enhancement, carrier selection, drug loading optimization, controlled release design, prototype formulation, and platform-specific characterization.
Small-Molecule Delivery Development Support
Our services help translate small-molecule physicochemical challenges into practical polymer carrier strategies, prototype systems, and measurable development outputs.
- Carrier selection based on solubility, logP, pKa, crystallinity, dose, and release goals
- Micelle, nanoparticle, microsphere, hydrogel, film, patch, insert, and implant strategies
- Drug loading, encapsulation, compatibility, and release profile evaluation
- Formulation optimization guidance for early-stage polymer delivery development
Why Small-Molecule Drug Delivery Requires a Polymer Strategy
Small-molecule drugs may appear simpler than biologics, but their delivery behavior is strongly influenced by solubility, hydrophobicity, ionization, crystallinity, chemical stability, dose requirement, and compatibility with the selected carrier. A successful small-molecule delivery system must connect molecular properties with polymer chemistry, formulation method, dosage form architecture, and release mechanism.
Polymer-based carriers can help address common formulation barriers through self-assembly, encapsulation, matrix incorporation, film formation, hydrogel networks, degradable particles, and diffusion-controlled or degradation-controlled release. BOC Sciences helps clients evaluate small-molecule delivery options from polymer selection through prototype preparation, drug loading, characterization, and release evaluation.
Property-Driven Carrier Design
Carrier design begins with the molecular profile of the active compound. Solubility, logP, pKa, melting point, crystallization tendency, molecular weight, chemical stability, and target release duration guide polymer selection, carrier architecture, processing conditions, and characterization priorities.
Solubility and Dispersion Enhancement
Poorly soluble and hydrophobic small molecules may benefit from polymer micelles, nanoparticles, PEGylated carriers, amorphous polymer matrices, or controlled-dispersion systems. These approaches can improve apparent dispersion while allowing carrier stability, loading level, and release behavior to be evaluated experimentally.
Controlled and Sustained Release Engineering
Polymer composition, molecular weight, end groups, hydrophilicity, degradation rate, particle size, matrix density, porosity, and device geometry influence small-molecule release. Rational formulation design helps reduce burst release, improve retention, and match release behavior with the intended development objective.
Common Challenges in Small-Molecule Delivery Development
Small-molecule delivery development often requires balancing solubility, loading, carrier stability, release control, route compatibility, and manufacturable preparation conditions. Challenges may vary greatly between a hydrophobic compound intended for nanoscale delivery and a small molecule requiring sustained release from a degradable polymer matrix.
Poor Aqueous Solubility
Low solubility can limit formulation screening, loading efficiency, release testing, and dose feasibility, making polymer micelles, nanoparticles, PEGylated carriers, or polymer matrices useful early-stage options.
Low Drug Loading or Encapsulation Efficiency
Weak drug-polymer compatibility may lead to poor loading, drug leakage, carrier disruption, or phase separation during preparation, storage, or release evaluation.
Initial Burst Release
Surface-associated drug, porous matrices, small particle size, or rapid water penetration can cause excessive early release in nanoparticles, microspheres, films, implants, or wafers.
Drug Crystallization
Small molecules with high crystallinity or poor polymer miscibility may recrystallize in carrier systems, affecting loading uniformity, storage behavior, and release reproducibility.
Carrier Instability or Aggregation
Nanoparticles and micelles may require careful control of particle size, PDI, zeta potential, CMC, dilution stability, medium compatibility, and storage conditions.
Route-Specific Formulation Constraints
Transdermal, local, injectable, ocular, mucosal, or implantable delivery goals impose different requirements on particle size, matrix integrity, adhesion, swelling, degradation, and release window.
Our Small-Molecule Drug Delivery Solution Portfolio
BOC Sciences provides customized small-molecule delivery services covering polymer carrier screening, micelle development, nanoparticle formulation, PLGA microsphere systems, hydrogel matrices, films, patches, inserts, wafers, and implantable polymer systems. Each option can be evaluated according to the drug properties, release target, route requirement, and available sample amount.
Polymer Carrier Screening
We evaluate candidate polymers and carrier families according to the compound's solubility, hydrophobicity, ionization, crystallinity, stability, target dose, and desired release profile.
- Biodegradable polymer and copolymer selection
- PEG and derivative compatibility assessment
- Drug-polymer interaction and miscibility review
Polymer Micelle Development
Polymer micelles are useful for hydrophobic and poorly soluble small molecules that require nanoscale dispersion, apparent solubility improvement, and self-assembled carrier design.
- Amphiphilic block copolymer selection
- CMC, micelle stability, and dilution behavior evaluation
- Drug loading, encapsulation, and release profiling
Polymer Nanoparticle Formulation
Polymeric nanoparticles can support small-molecule encapsulation, dispersion, controlled release, and surface property tuning using degradable or functional polymer systems.
- Nanoprecipitation, emulsification, or solvent diffusion approaches
- Particle size, PDI, zeta potential, and morphology control
- PLGA, PLA, PCL, PEGylated, and functional polymer systems
Polymer Microsphere and Sustained-Release Systems
Microsphere systems are suitable for small molecules requiring sustained release, depot-like behavior, reduced burst release, or biodegradable matrix-based delivery development.
- PLGA, PLA, PCL, and related degradable microspheres
- Particle size, porosity, morphology, and drug distribution control
- In vitro release and degradation-linked evaluation
Hydrogel and In Situ Matrix Systems
Hydrogel and network-based systems can support local retention, hydrated diffusion environments, swelling-controlled release, and mild formulation conditions for selected small molecules.
- PEG, PVA, alginate, chitosan, and functional hydrogel systems
- Gelation, crosslinking, swelling, and degradation tuning
- Small-molecule diffusion and release evaluation
Film, Patch, Insert, Wafer, and Implant Systems
Solid or semi-solid polymer matrices can be designed for localized exposure, transdermal development, thin-film delivery, insert-like formats, wafer systems, or long-acting implants.
- Matrix casting, coating, molding, and implant fabrication
- Drug distribution, migration, crystallization, and release assessment
- Polymer flexibility, thickness, swelling, and degradation evaluation
Need a Carrier Strategy for a Difficult Small Molecule?
Share your compound structure, solubility profile, logP, pKa, target release duration, intended route, and current formulation challenge. We can help evaluate polymer micelles, nanoparticles, microspheres, hydrogels, films, or matrix-based delivery options.
Polymer Carrier Strategies for Small-Molecule Delivery
BOC Sciences provides integrated polymer material selection and formulation development support for small-molecule drug delivery systems, covering polymer design consultation, carrier screening, and prototype formulation development. Our expertise in polymer chemistry, controlled release systems, and drug–polymer interaction engineering enables rational selection of suitable polymer classes based on physicochemical properties of small molecules.
Biodegradable Polyesters
This class of polymers provides hydrolysis-driven degradation behavior and is widely used in sustained and controlled release systems. Drug release is primarily regulated by polymer erosion, diffusion, and matrix structural evolution over time.
- Used for microspheres, nanoparticles, implants, and depot systems
- Supports long-acting and sustained release formulation design
- Degradation rate tunable via polymer composition and molecular weight
Amphiphilic Block Copolymer Systems
Amphiphilic polymer systems self-assemble into micelles or vesicles in aqueous environments, enabling hydrophobic drug encapsulation within a core–shell structure. These systems are widely used for solubility enhancement and nanoscale delivery.
- Self-assembled micelle and vesicle formation systems
- Hydrophobic core and hydrophilic shell architecture
- CMC-dependent stability and drug loading behavior
Hydrophilic Polymer Networks
Hydrophilic polymers form gel-like networks capable of controlling drug diffusion through swelling behavior and mesh size regulation. These materials are suitable for localized delivery and diffusion-controlled release systems.
- Swelling-controlled and diffusion-controlled release mechanisms
- Injectable or preformed hydrogel systems
- Suitable for local retention and soft tissue delivery
Hydrophobic Thermoplastic Polymers
Hydrophobic thermoplastics provide physically stable matrices with slow water penetration and extended drug release profiles. They are commonly used in solid dosage forms requiring long-term structural integrity.
- Matrix-based films, implants, and depot systems
- Slow diffusion-controlled release behavior
- High structural stability and mechanical strength
Functionalized Polymer Systems
Functionalized polymers incorporate reactive or interactive chemical groups that enable improved drug–polymer compatibility, enhanced loading efficiency, and tunable intermolecular interactions such as hydrogen bonding, ionic interaction, or π–π stacking.
- Enhanced drug–polymer interaction capability
- Improved encapsulation and loading stability
- Support for tailored release profile engineering
Responsive Polymer Systems
Responsive polymer systems are designed to adjust their physical or chemical behavior in response to environmental triggers such as pH, temperature, redox conditions, or ionic strength, enabling controlled and on-demand drug release.
- pH-, temperature-, or redox-responsive mechanisms
- On-demand or trigger-controlled drug release behavior
- Adaptive structural changes under physiological conditions
How to Select a Delivery Strategy for Small-Molecule Drugs
Small-molecule drugs may require different polymer delivery strategies depending on their therapeutic use, solubility profile, potency, tissue distribution, release requirement, and sensitivity to degradation. Polymer-based carriers can help improve aqueous dispersion, protect unstable compounds, reduce burst exposure, support sustained release, or enhance local and targeted delivery.
| Small-Molecule Drugs | Key Delivery Challenges | Suitable Polymer Strategies | Key Evaluation Points |
|---|---|---|---|
| Hydrophobic or Poorly Water-Soluble Small Molecules | Low aqueous solubility, poor dissolution, precipitation after dilution, limited bioavailability | Polymer micelles, polymer nanoparticles, PEGylated carriers, amphiphilic block copolymer systems, solid dispersion matrices | Apparent solubility, particle size, drug loading, dilution stability, precipitation risk, dissolution and release behavior |
| Anticancer Small Molecules | High potency, narrow therapeutic window, systemic toxicity, poor tumor accumulation, rapid clearance | Polymeric nanoparticles, polymer-drug conjugates, micelles, targeted polymer carriers, injectable depot systems | Loading efficiency, cytotoxicity profile, release kinetics, carrier stability, tumor-relevant release behavior, residual solvent control |
| Anti-Inflammatory Small Molecules | Need for localized exposure, gastrointestinal or systemic side effects, short residence time, repeated dosing burden | Hydrogels, polymer films, microspheres, nanoparticles, topical or injectable polymer matrices | Local retention, sustained release, tissue compatibility, drug-polymer interaction, inflammation-site exposure, burst release control |
| Anti-Infective Small Molecules | Short half-life, poor tissue penetration, local concentration requirements, resistance-related dosing concerns | Polymer nanoparticles, hydrogels, coatings, microspheres, mucoadhesive polymer systems, implantable matrices | Release duration, local drug concentration, antimicrobial activity retention, matrix compatibility, sterilization impact, biofilm-related performance |
| Hormone and Steroid Small Molecules | High lipophilicity, need for long-acting release, dose control requirements, fluctuation-related side effects | PLGA microspheres, polymer implants, injectable depots, polymer films, biodegradable matrix systems | Release duration, burst release, dose uniformity, polymer degradation rate, residual drug content, long-term stability |
| Central Nervous System Small Molecules | Limited bioavailability, controlled exposure needs, possible blood-brain barrier limitations, sensitivity to plasma fluctuation | Polymer nanoparticles, PEGylated carriers, intranasal polymer systems, sustained-release matrices, surface-modified carriers | Particle size, surface properties, release profile, stability in biological media, mucosal compatibility, exposure consistency |
| Immunomodulatory Small Molecules | Systemic immune effects, need for controlled exposure, tissue-specific activity, low-dose formulation requirements | Targeted polymer nanoparticles, polymer-drug conjugates, hydrogels, microspheres, immune-cell-interactive polymer carriers | Dose precision, immune-cell interaction, release control, carrier biocompatibility, tissue distribution, inflammatory response |
How We Develop Small-Molecule Delivery Systems
BOC Sciences provides development services that connect polymer chemistry, carrier preparation, formulation screening, analytical characterization, and release evaluation. Projects may be structured as feasibility assessments, platform comparisons, prototype development programs, carrier optimization studies, or focused problem-solving tasks.
Drug Property and Formulation Risk Assessment
We review compound properties and development goals before recommending a carrier strategy. This helps identify whether the main challenge is solubility, loading, stability, burst release, crystallization, route compatibility, or matrix retention.
- Structure, molecular weight, logP, pKa, and solubility review
- Stability, crystallinity, dose, and release target assessment
- Early identification of formulation risk factors
Polymer and Carrier Selection
Polymer candidates are selected according to degradability, amphiphilicity, molecular weight, functional groups, miscibility, carrier-forming ability, and compatibility with the target small molecule.
- Lactide and glycolide polymer evaluation
- Caprolactone polymer selection for slow-degrading matrices
- Custom polymer synthesis options when standard materials are insufficient
Prototype Formulation Development
Prototype systems are prepared using carrier-specific methods, including self-assembly, nanoprecipitation, emulsification, solvent evaporation, gelation, film casting, coating, molding, or matrix fabrication.
- Micelle, nanoparticle, microsphere, hydrogel, and film prototypes
- Small-batch screening under controlled formulation variables
- Preparation method refinement based on carrier behavior
Drug Loading and Encapsulation Optimization
Loading conditions are adjusted to improve compatibility, reduce drug leakage, control crystallization, and obtain a practical balance between drug content, carrier stability, and release performance.
- Drug-polymer ratio and solvent system evaluation
- Encapsulation efficiency and loading capacity optimization
- Compatibility and precipitation risk assessment
Characterization and Release Evaluation
Analytical methods are selected according to carrier type and project objective. Characterization may include particle size, morphology, surface behavior, thermal analysis, structural evaluation, loading assay, and in vitro release profiling.
- Polymer characterization and carrier performance evaluation
- HPLC or UPLC-based drug content and release analysis when applicable
- DSC, XRD, FTIR, GPC, SEM, TEM, DLS, and zeta potential options
Optimization and Development Recommendations
We interpret formulation data to identify relationships between polymer chemistry, carrier architecture, preparation conditions, and release behavior, then provide practical recommendations for next-stage development.
- Polymer composition and molecular weight adjustment
- Carrier architecture, matrix structure, or process refinement
- Suggested next experiments based on observed limitations
Small-Molecule Drug Delivery Development Workflow
Our workflow is designed to move small-molecule delivery projects from problem definition to polymer carrier selection, prototype formulation, characterization, release evaluation, and optimization planning. Each step focuses on connecting formulation decisions with measurable development data.
Project Requirement Review
We begin by collecting available information about the small molecule, including structure, molecular weight, solubility, logP, pKa, crystallinity, chemical stability, dose target, intended route, release duration, and available sample amount. This review clarifies whether the primary objective is solubility enhancement, sustained release, local retention, carrier comparison, or formulation troubleshooting. It also helps identify missing data that may influence polymer selection or analytical method planning.
Carrier Strategy Shortlisting
Candidate delivery strategies are shortlisted by matching the compound's limitations with suitable carrier mechanisms. Hydrophobic compounds may be considered for polymer micelles or nanoparticles, while projects requiring long exposure may be directed toward microspheres, implants, wafers, or degradable matrices. The shortlisting stage compares feasibility, loading logic, route compatibility, expected release mechanism, and formulation risk before experimental work begins.
Polymer and Method Selection
Suitable polymers and preparation methods are selected according to drug-polymer compatibility, degradation behavior, hydrophilicity, functional groups, molecular weight, processing tolerance, and target dosage form. Depending on the selected carrier, methods may include self-assembly, nanoprecipitation, emulsification, solvent evaporation, gelation, crosslinking, film casting, coating, or matrix fabrication. This stage establishes the experimental framework for prototype preparation.
Prototype Preparation
Initial prototype formulations are prepared under controlled conditions to evaluate carrier formation, drug incorporation, physical stability, and early feasibility. Multiple formulation variables may be explored, such as polymer type, drug-polymer ratio, solvent system, stirring or mixing parameters, emulsifier selection, crosslink density, film thickness, or matrix geometry. Prototype preparation provides the first practical evidence for whether the selected polymer strategy is suitable.
Drug Loading and Compatibility Screening
Drug loading, encapsulation efficiency, compatibility, and physical state are evaluated to determine whether the small molecule is retained effectively within the polymer carrier. This step may reveal issues such as low loading, drug leakage, surface enrichment, precipitation, crystallization, or carrier destabilization. Findings from this stage guide adjustments to polymer composition, processing conditions, carrier architecture, or drug incorporation method.
Characterization and Release Testing
Prototype systems are characterized using methods appropriate for the selected platform. Nanocarriers may require particle size, PDI, zeta potential, morphology, and dilution stability analysis, while polymer matrices may require swelling, degradation, thermal behavior, morphology, mechanical behavior, or drug distribution assessment. In vitro release testing is designed to evaluate burst release, sustained release behavior, and the relationship between carrier structure and drug liberation.
Data Interpretation
Experimental data are interpreted to identify how polymer chemistry, drug-polymer interaction, carrier architecture, particle morphology, matrix structure, and process conditions affect loading and release behavior. This step helps distinguish whether poor performance arises from polymer incompatibility, crystallization, rapid diffusion, unstable carrier assembly, inadequate matrix density, or unsuitable analytical conditions. Clear interpretation supports rational optimization rather than repeated trial-and-error formulation.
Optimization Recommendations
Based on the observed formulation performance, we provide practical recommendations for next-stage development. Suggestions may include changing polymer molecular weight, adjusting copolymer composition, modifying hydrophilic-hydrophobic balance, altering particle size, reducing porosity, changing loading method, refining release media, or comparing an alternative carrier platform. The final recommendations are aligned with project scope, sample availability, and the intended formulation direction.
Deliverables for Small-Molecule Delivery Projects
Deliverables are tailored to the project scope and may include carrier selection rationale, polymer recommendations, prototype formulations, loading data, characterization results, release profiles, and development recommendations. These outputs help clients compare polymer delivery options and decide whether to optimize, scale, or redirect the formulation strategy.
Carrier Selection Rationale
Summarizes the compound properties, delivery objective, formulation risks, candidate polymer carriers, and recommended development direction.
Polymer and Material Recommendation
Provides suggested polymer classes, molecular weight considerations, functional group logic, degradability factors, and carrier suitability notes.
Prototype Formulation Samples
May include micelles, nanoparticles, microspheres, hydrogels, films, patches, inserts, wafers, implants, or other polymer matrices based on project scope.
Drug Loading and Encapsulation Data
Includes loading level, encapsulation efficiency, compatibility observations, drug leakage risk, precipitation behavior, or crystallization-related findings.
Characterization Data Package
May include particle size, PDI, zeta potential, morphology, thermal behavior, structural analysis, swelling, degradation, or matrix property data.
In Vitro Release Evaluation Report
Provides release profiles, burst release observations, sustained-release comparison, analytical conditions, and interpretation of formulation behavior.
Why Choose BOC Sciences for Small-Molecule Delivery Solutions
BOC Sciences integrates polymer chemistry, carrier engineering, formulation screening, analytical characterization, and controlled-release development experience to help clients address small-molecule delivery challenges with practical, data-supported polymer strategies.
Polymer Chemistry Expertise
Polymer composition, architecture, molecular weight, end groups, degradability, amphiphilicity, and functional groups can be considered during carrier design and optimization.
Multiple Carrier Platform Options
We support micelles, nanoparticles, microspheres, hydrogels, films, patches, inserts, wafers, implants, and related polymer matrix systems for small-molecule delivery.
Property-Based Formulation Thinking
Carrier selection is guided by compound properties, release goals, route requirements, and formulation risks rather than by a fixed platform template.
Integrated Characterization Capability
Analytical evaluation helps connect formulation variables with loading behavior, carrier stability, morphology, drug state, and release profile interpretation.
Flexible Project Scope
Projects can be structured as feasibility assessments, platform comparisons, prototype development programs, release studies, or focused troubleshooting tasks.
Clear Development Communication
Deliverables are organized around decision-making needs, helping clients understand carrier options, formulation limitations, and practical next development steps.
Frequently Asked Questions
These questions address common considerations for small-molecule drug delivery projects, including polymer carrier selection, solubility improvement, release control, sample information, and formulation development scope.
What types of small molecules can be evaluated for polymer-based delivery?
We can evaluate poorly soluble, hydrophobic, amphiphilic, crystalline, rapidly diffusing, or stability-sensitive small molecules for polymer-based delivery. Useful starting information includes chemical structure, molecular weight, solubility, logP, pKa, melting point, stability data, target release duration, route expectation, available sample amount, and any previous formulation results or failure points.
Which polymer carrier is suitable for poorly soluble small molecules?
Poorly soluble small molecules are often assessed with polymer micelles, polymer nanoparticles, PEGylated carriers, amorphous polymer matrices, or degradable polymer systems. The preferred option depends on hydrophobicity, dose requirement, target route, release window, and compatibility with the polymer phase. Screening is usually needed before selecting a final carrier direction.
Can polymer micelles improve small-molecule solubility?
Polymer micelles may improve apparent dispersion of hydrophobic small molecules by placing the drug in a compatible hydrophobic core while presenting a hydrophilic outer shell. Suitability depends on loading capacity, CMC, dilution stability, polymer-drug compatibility, release behavior, and whether the compound remains physically stable during preparation, storage, and testing.
How do you reduce burst release in small-molecule polymer systems?
Burst release can be reduced by adjusting polymer molecular weight, copolymer composition, end groups, drug-polymer ratio, particle size, matrix porosity, coating structure, or preparation conditions. The best strategy depends on whether early release comes from surface-associated drug, rapid water penetration, poor miscibility, high diffusion rate, or unstable carrier architecture.
What sample information is needed before starting?
Helpful information includes chemical structure, molecular weight, purity, solubility in water and organic solvents, logP, pKa, stability profile, target dosage form, desired release duration, intended route, available sample quantity, analytical method availability, and previous formulation attempts. If some information is unavailable, the project can begin with a focused feasibility assessment.
Can you compare multiple delivery platforms for one small molecule?
Yes. A single small molecule can be compared across micelles, nanoparticles, microspheres, hydrogels, films, or polymer matrices when the best platform is uncertain. Comparative screening helps identify differences in loading, carrier stability, release behavior, processing feasibility, and route compatibility before committing resources to a more detailed optimization program.
Do you provide release testing for small-molecule formulations?
Release testing can be included when suitable analytical methods and formulation samples are available. Test design may consider release medium, sink conditions, sampling schedule, drug stability, and assay method. Results can help evaluate burst release, sustained release, incomplete release, carrier degradation effects, and the relationship between polymer structure and drug liberation.
Can the polymer carrier be customized for a specific small molecule?
Yes. Polymer carriers can be customized by adjusting composition, molecular weight, architecture, hydrophilic-hydrophobic balance, end groups, functional groups, crosslinking density, degradation rate, or carrier geometry. Customization is guided by drug properties, loading behavior, release target, matrix compatibility, and the formulation problems observed during early prototype evaluation.
Submit Your Drug Delivery Project Inquiry
Please share your small-molecule structure, solubility profile, logP, pKa, stability information, intended route, desired release duration, preferred delivery format, current formulation challenge, and available sample amount. Our team can help propose a suitable polymer carrier strategy and development plan.
- Polymer carrier selection for small molecules
- Poor solubility and hydrophobic drug formulation development
- Micelle, nanoparticle, microsphere, hydrogel, film, patch, insert, and implant systems
- Drug loading, compatibility, characterization, and release evaluation
- Custom polymer design and formulation optimization guidance
